Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Replimune Group ( (REPL) ) has provided an update.
On January 29, 2026, Replimune Group amended its loan and security agreement with Hercules Capital, extending a key revenue milestone to September 30, 2027, adjusting tranche sizes, and pushing the start of debt amortization from October 1, 2026 to October 1, 2027, while immediately drawing a $35 million third tranche and securing access to an additional $120 million tied to post-approval milestones. Reporting fiscal third-quarter 2026 results for the period ended December 31, 2025, the company highlighted FDA acceptance in October 2025 of its resubmitted BLA for lead therapy RP1 in anti-PD-1 failed advanced melanoma with an April 10, 2026 PDUFA date, ongoing Phase 3 and other late-stage trials for RP1 and RP2 across melanoma, non-melanoma skin cancers and liver-related cancers, and a cash position of $269.1 million that, together with the revised debt facility, is expected to fund operations and commercial launch preparations for RP1 into late first quarter 2027 despite rising R&D and SG&A expenses and a quarterly net loss of $70.9 million.
The most recent analyst rating on (REPL) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Replimune Group stock, see the REPL Stock Forecast page.
Spark’s Take on REPL Stock
According to Spark, TipRanks’ AI Analyst, REPL is a Neutral.
The score is held down primarily by weak financial performance (no revenue, widening losses, and heavy cash burn) and bearish technical momentum. Offsetting these, corporate events are a meaningful positive given the FDA acceptance and defined April 2026 decision date plus stated launch preparation, but valuation remains unfavorable due to ongoing losses and no dividend support.
To see Spark’s full report on REPL stock, click here.
More about Replimune Group
Replimune Group, Inc., headquartered in Woburn, Massachusetts, is a clinical-stage biotechnology company focused on developing novel oncolytic immunotherapies for cancer using its proprietary RPx platform based on a potent HSV-1 backbone. Its lead product candidates, RP1 and RP2, are engineered herpes simplex virus therapies designed to maximize tumor killing, enhance the immunogenicity of tumor cell death, and trigger systemic anti-tumor immune responses, with the potential to be used alone or in combination with existing and experimental cancer treatments across multiple solid tumor indications.
Average Trading Volume: 1,624,766
Technical Sentiment Signal: Strong Sell
Current Market Cap: $551.5M
For an in-depth examination of REPL stock, go to TipRanks’ Overview page.